trial
as of 2026-07-01Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia
NCTId NCT00728728
at a glance
Phase 2 · Completed
Enrollment 88 (actual)
Sponsored by VA Office of Research and Development
Primary completion 2015-03
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
88 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2009-12
Primary completion
2015-03
Eligibility
ALL · 21 Years · 65 Years
Interventions & indications
Sponsors
VA Office of Research and DevelopmentLead Sponsor
Investigators
1
Christine E Marx, MD, MAPrincipal Investigator
Sites
1 total
Durham, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
88
Phase
PHASE2
Primary Completion Date
2015-03
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
indication
investigator
person